Kiniksa Pharmaceuticals(KNSA)
$93.54-1.52 (-1.59%)
KNSA
Kiniksa Pharmaceuticals financials statements
$93.54
At close:-1.52 (-1.59%)
Want to see KNSA full AI Analyst Report?
Kiniksa Pharmaceuticals (KNSA) Ratios
620 Followers
Kiniksa Pharmaceuticals Ratios
KNSA's free cash flow for Q3 2026 was $47.10M. For the 2026 fiscal year, KNSA's free cash flow was decreased by $-180.00K and operating cash flow was $47.28M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.79 | 3.30 | 4.34 | 5.16 | 4.38 |
| Quick Ratio | 3.39 | 3.04 | 3.85 | 4.71 | 4.30 |
| Cash Ratio | 1.19 | 1.82 | 1.70 | 2.61 | 2.73 |
| Solvency Ratio | 0.31 | -0.29 | 0.19 | 2.92 | -3.26 |
| Operating Cash Flow Ratio | 0.18 | 0.26 | 0.21 | 0.12 | -2.82 |
| Short-Term Operating Cash Flow Coverage | 8.60 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 331.15M | $ 189.68M | $ 188.81M | $ 179.54M | $ 148.68M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.02 | 0.02 | 0.01 | 0.03 |
| Debt-to-Equity Ratio | 0.02 | 0.02 | 0.03 | 0.01 | 0.03 |
| Debt-to-Capital Ratio | 0.02 | 0.02 | 0.03 | 0.01 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.35 | 1.32 | 1.20 | 1.16 | 1.26 |
| Debt Service Coverage Ratio | 20.27 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.13 | 0.14 | 0.17 | 0.09 | 0.09 |
| Net Debt to EBITDA | -1.73 | 5.04 | 4.19 | -9.59 | 0.75 |
| Profitability Margins | |||||
| Gross Profit Margin | 54.63% | 85.61% | 79.09% | 89.60% | 76.39% |
| EBIT Margin | 13.12% | -8.54% | -9.32% | 4.44% | -406.38% |
| EBITDA Margin | 13.35% | -8.14% | -8.46% | 5.53% | -400.27% |
| Operating Profit Margin | 11.40% | -10.78% | -9.32% | 4.44% | -406.38% |
| Pretax Profit Margin | 13.12% | -8.54% | -6.16% | 5.01% | -406.13% |
| Net Profit Margin | 8.71% | -10.21% | 5.21% | 83.28% | -409.72% |
| Continuous Operations Profit Margin | 8.71% | -10.21% | 5.21% | 83.28% | -409.72% |
| Net Income Per EBT | 66.40% | 119.48% | -84.58% | 1663.01% | 100.88% |
| EBT Per EBIT | 115.08% | 79.25% | 66.09% | 112.82% | 99.94% |
| Return on Assets (ROA) | 7.73% | -7.44% | 2.68% | 39.89% | -67.84% |
| Return on Equity (ROE) | 10.40% | -9.85% | 3.21% | 46.29% | -85.35% |
| Return on Capital Employed (ROCE) | 12.37% | -9.50% | -5.45% | 2.37% | -83.33% |
| Return on Invested Capital (ROIC) | 8.17% | -9.47% | 4.58% | 2.35% | -81.86% |
| Return on Tangible Assets | 7.88% | -7.65% | 2.77% | 41.54% | -73.95% |
| Earnings Yield | 1.93% | -3.06% | 1.15% | 17.64% | -19.57% |
| Efficiency Ratios | |||||
| Receivables Turnover | 43.45 | 10.14 | 12.71 | 10.84 | 9.67 |
| Payables Turnover | 151.58 | 29.87 | 6.85 | 2.90 | 4.87 |
| Inventory Turnover | 5.60 | 2.31 | 1.82 | 1.06 | 2.48 |
| Fixed Asset Turnover | 57.67 | 38.34 | 21.34 | 31.26 | 4.60 |
| Asset Turnover | 0.89 | 0.73 | 0.51 | 0.48 | 0.17 |
| Working Capital Turnover Ratio | 2.19 | 1.91 | 1.32 | 1.27 | 0.17 |
| Cash Conversion Cycle | 71.17 | 181.75 | 176.44 | 252.09 | 110.22 |
| Days of Sales Outstanding | 8.40 | 35.98 | 28.72 | 33.68 | 37.74 |
| Days of Inventory Outstanding | 65.18 | 157.98 | 200.97 | 344.34 | 147.40 |
| Days of Payables Outstanding | 2.41 | 12.22 | 53.25 | 125.93 | 74.93 |
| Operating Cycle | 73.58 | 193.97 | 229.69 | 378.02 | 185.14 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.35 | 0.36 | 0.19 | 0.08 | -1.84 |
| Free Cash Flow Per Share | 0.34 | 0.36 | 0.19 | 0.08 | -2.14 |
| Dividend Paid and CapEx Coverage Ratio | 92.74 | 92.74 | 102.32 | 55.30 | -6.19 |
| Capital Expenditure Coverage Ratio | 92.74 | 92.74 | 102.32 | 55.30 | -6.19 |
| Operating Cash Flow Coverage Ratio | 2.70 | 2.61 | 1.09 | 0.98 | -20.88 |
| Operating Cash Flow to Sales Ratio | 0.04 | 0.06 | 0.05 | 0.03 | -3.28 |
| Free Cash Flow Yield | 0.83% | 1.80% | 1.07% | 0.55% | -18.18% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 51.56 | -32.97 | 87.25 | 5.67 | -5.11 |
| Price-to-Sales (P/S) Ratio | 4.52 | 3.34 | 4.55 | 4.72 | 20.94 |
| Price-to-Book (P/B) Ratio | 5.39 | 3.22 | 2.80 | 2.62 | 4.36 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 120.45 | 55.59 | 93.30 | 182.28 | -5.50 |
| Price-to-Operating Cash Flow Ratio | 119.15 | 55.00 | 92.39 | 178.98 | -6.39 |
| Price-to-Earnings Growth (PEG) Ratio | -0.22 | 0.08 | -0.94 | -0.03 | 0.43 |
| Enterprise Value Multiple | 32.12 | -35.96 | -49.58 | 75.77 | -4.48 |
| Enterprise Value | 2.90B | 1.24B | 1.13B | 922.55M | 690.73M |
| EV to EBITDA | 32.12 | -35.96 | -49.58 | 75.77 | -4.48 |
| EV to Sales | 4.29 | 2.93 | 4.19 | 4.19 | 17.92 |
| EV to Free Cash Flow | 114.30 | 48.76 | 86.03 | 161.79 | -4.71 |
| EV to Operating Cash Flow | 113.07 | 48.23 | 85.19 | 158.87 | -5.47 |
| Tangible Book Value Per Share | 7.44 | 5.91 | 6.02 | 5.45 | 2.42 |
| Shareholders’ Equity Per Share | 7.65 | 6.14 | 6.26 | 5.71 | 2.70 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.34 | -0.19 | 1.85 | -15.63 | -0.01 |
| Revenue Per Share | 9.13 | 5.93 | 3.86 | 3.17 | 0.56 |
| Net Income Per Share | 0.80 | -0.60 | 0.20 | 2.64 | -2.30 |
| Tax Burden | 0.66 | 1.19 | -0.85 | 16.63 | 1.01 |
| Interest Burden | 1.00 | 1.00 | 0.66 | 1.13 | 1.00 |
| Research & Development to Revenue | 0.14 | 0.26 | 0.28 | 0.30 | 2.58 |
| SG&A to Revenue | 0.29 | 0.40 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.05 | 0.07 | 0.10 | 0.11 | 0.65 |
| Income Quality | -0.59 | -0.59 | 0.94 | 0.03 | 0.80 |
Currency in USD

